Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
Oryzon will launch its first product onto the market
Oryzon to Present at CTAD 2010 Conference in Toulouse, France.
Early diagnostic in cancer is essential to obtain more effective treatments for the disease. ORYZON has performed extensive genomic surveys in several cancers.
Our current product pipeline is:
